Saffery Champness’ London Corporate Finance Team, led by Niraj Patel and with assistance from our Nexia associates in the USA and China, has recently provided financial and tax due diligence to Biosynth in support of its acquisition of Carbosynth.
Both companies have diverse expertise in organic synthesis and different focuses in their product portfolio of bio-chemicals.
Biosynth is a leader in the field of biochemicals for the diagnostics, pharmaceutical and chemical industries as well as food and environmental analysis. With its headquarters and main production in Switzerland and sites in Slovakia, the USA and China, Biosynth offers a product base of over 100,000 substances.
Since its establishment in 2006, Carbosynth has built a global organisation with operations in the UK, USA and China and is a leading worldwide supplier of carbohydrates, nucleosides and biochemicals to research and development scientists in the pharmaceutical and biotechnology industries.
Dr. Urs Spitz, President of Biosynth said “Since both companies have a complementary product offering and technical know-how, and have been successfully working together on joint projects, this acquisition seems like a natural progression.” Together they form a leading player in the global fine chemicals market.